IP Infusion's OcNOS® provides a feature-rich upgrade platform for French internet and managed service provider
SANTA CLARA, Calif., March 27, 2024 – IP Infusion, the market leader in carrier-grade networking software systems, announced today that Prosoluce, an internet and managed service provider based in France, has chosen to upgrade its backbone network with IP Infusion software and 100G open networking hardware from Edgecore Networks. Open networking systems integrator Pine Networks, which specializes in open, disaggregated, and virtualized solutions, guided Prosoluce through this journey of backbone upgrade.
Prosoluce is a regional internet service provider, cloud provider, and managed services provider. Responding to growing demand and addressing upgrade limitations with its 10G backbone network, Prosoluce는 멀티사이트·멀티테넌트 서비스 제공이 가능한 최첨단 EVPN-VXLAN 기술 기반의 새로운 IP 백본을 구축하기로 결정했습니다. After evaluating a competitive field of traditional vendor solutions and refurbished options, disaggregation with IP Infusion came as the best offering. Support from IP Infusion and Pine Networks was decisive in this evaluation process as Prosoluce refined its expectations.
Choosing an upgrade to its existing backbone posed specific interoperating challenges. The new solution required compatibility with Prosoluce's existing networking vendors, which at the time consisted of Alcatel Lucent, Huawei, MikroTik, and Ubiquiti equipment.
"Prosoluce's upgrade to open networking solved several problems at once," said Gaël Hermet, Directeur Général for Prosoluce. "Together with the benefits of a competitive technology and supported interoperability, we valued Pine Networks' recommendation for open networking to avoid single traditional vendor lock-in. IP Infusion software allowed for increased compatibility and performance while lowering costs."
"The benefits of open networking become clear as more organizations look into the Total Cost of Ownership of their network infrastructure," said Hadi Choueiry, General Manager for Pine Networks. "Perhaps more important than cost, open networking solutions provide our customers the flexibility and openness they need."
"With the support of partners and customers such as Pine Networks and Prosoluce, IP Infusion is working to be the open networking software vendor alternative to the networking industry," said Atsushi Ogata, President and CEO of IP Infusion. "Commercial application, an industry-leading price, and robust support are hallmarks of IP Infusion products."
IP Infusion 소개
IP Infusion manufactures open network software and solutions for carriers, service providers, and data centers. With hundreds of customers and thousands of deployments, IP Infusion is a market leader in Network Operating Systems. Our flagship software platform OcNOS® allows network operators to disaggregate their networks, streamline operations, and reduce Total Cost of Ownership (TCO). Network OEMs may also disaggregate network devices to expedite time to market, offer comprehensive services, and achieve carrier-grade robustness.
IP Infusion is headquartered in Santa Clara, Calif., and is a wholly owned and independently operated subsidiary of ACCESS CO., LTD. Additional information can be found at http://www.IPInfusion.com.
IP Infusion and OcNOS are trademarks or registered trademarks of IP Infusion. ACCESS is a registered trademark or trademark of ACCESS CO., LTD. in the United States, Japan and/or other countries. Northforge Innovations is a registered trademark of Northforge Innovations, Inc. All other trademarks, service marks, registered trademarks, or registered service marks mentioned are the property of their respective owners.
-end-
Media Contact:
Katherine Verducci
1903 PR
kverducci@1903pr.com
408.429.5779
IP Infusion 소개
IP Infusion은 오픈 네트워킹 소프트웨어의 선도적 공급업체로, 서비스 사업자, 데이터센터, AI 패브릭 네트워크를 위한 통신사업자급 네트워크 운영체제 OcNOS를 제공합니다. 1999년부터 쌓아 온 네트워킹 전문성과 전 세계 600개 이상의 사업자를 바탕으로, IP Infusion은 Edgecore Networks, UfiSpace, Celestica 등 파트너의 검증된 개방형 하드웨어에서 개방적이고 멀티벤더이며 비용 효율적이고 유연한 네트워크 인프라를 구현합니다. IP Infusion은 ACCESS CO., LTD.(도쿄증권거래소: 4813)의 전액 출자 자회사입니다.
미디어 문의
For press inquiries, analyst briefings, or media materials, please 팀에 문의 or email pr@ipinfusion.com.
미래예측 진술
본 보도자료에는 IP Infusion의 제품, 기술 및 계획에 관한 미래예측 진술이 포함될 수 있습니다. 미래예측 진술은 공개일 현재 이용 가능한 정보에 기초하며 위험과 불확실성을 수반합니다. 실제 결과는 다를 수 있습니다. 제품 계획, 기능, 출시 시기 및 제공 여부는 예고 없이 변경될 수 있으며 약정, 약속 또는 법적 의무를 구성하지 않습니다. IP Infusion은 미래예측 진술을 갱신할 의무를 지지 않습니다.